The anti-parkinson drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Anti-Parkinson Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The anti-parkinson drugs market size has grown strongly in recent years. It will grow from $9.73 billion in 2023 to $10.43 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to aging population, increasing disease prevalence, healthcare infrastructure, advancements in research.
The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $13.36 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing awareness, biotechnological advancements, emerging markets. Major trends in the forecast period include investment in r&d, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine and remote monitoring, biosimilars, research collaborations.
Order your report now for swift delivery @
Scope Of Anti-Parkinson Drugs Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Anti-Parkinson Drugs Market Overview
Market Drivers –
The increasing geriatric population and surging cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60 cases of Parkinson’s disease (PD) are projected to drive the demand for the anti-Parkinson drugs market. PD commonly occurs in people over the age of 60. For instance, in October 2022, according to the World Health Organization, a US-based health agency, Globally, 1 in 6 individuals will be 60 or older by 2030, and by 2050, there will be a double amount of individuals in this age group (2.1 billion). Additionally, for instance, in June 2021, according to the UK Parliament’s House of Commons Library, a UK-based information resource, the elderly population in the UK will increase, accounting for 24% of the total population (17.4 million people) by 2043. Therefore, the increasing geriatric population is driving the growth of the anti-parkinson drugs market.
Market Trends –
Major companies operating in the anti-Parkinson drugs market are focusing on innovating products, such as Safinamide, to provide reliable services to customers. Safinamide is used as an anti-Parkinson drug for the treatment of Parkinson disease and to improve the quality of life of patients. For instance, in April 2021, Optimus Pharma Private Limited, an India-based pharmaceutical company, launched Safinamide, which was approved by the Drug Controller General of India (DCGI), which is the head of the Central Drugs Standard Control Organization (CDSCO), an India-based national regulatory authority. Safinamide is an anti-Parkinson drug indicated as adjunctive therapy to levodopa or carbidopa in patients with Parkinson disease. This will assist in delivering robust treatment for Parkinson’s disease with very high affordability and accessibility to patients.
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Get an inside scoop of the anti-parkinson drugs market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.
Table of Contents
1. Executive Summary
2. Anti-Parkinson Drugs Market Report Structure
3. Anti-Parkinson Drugs Market Trends And Strategies
4. Anti-Parkinson Drugs Market – Macro Economic Scenario
5. Anti-Parkinson Drugs Market Size And Growth
…..
27. Anti-Parkinson Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Twitter: https://twitter.com/tbrc_info
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
